Skip to main content

WaferGen Subsidiary Raising $5M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today announced that its Malaysian subsidiary has signed a purchase agreement with an investor for a $5 million private placement.

The investor, the Malaysian Technology Development Corporation, will purchase the subsidiary's Series C-1 redeemable convertible preference shares at a price of $1.55 per share. MTDC has the right to acquire up to $2.5 million of Series C-2 preference shares of the subsidiary at $2.32 per share for up to 36 months after the closing, which is expected this month.

The redeemable convertible preference shares will be converted into shares of WaferGen Biosystems common stock on a one-for-one basis within one year of issuance, WaferGen said in a statement. MTDC had previously invested in WaferGen Biosystems.

WaferGen said that it plans to use net proceeds from the financing for general corporate and working capital purposes, including broad commercialization of its SmartChip Real-Time PCR system launched in August.

On Tuesday, the Fremont, Calif.-based company disclosed in a filing with the US Securities and Exchange Commission a $2 million loan agreement with Oxford Finance Corp.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.